Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4425 - Type VI collagen (COL6) as part of tumorgenesis – focus on quantifying specific COL6 protein fragments in serum

Date

11 Sep 2017

Session

Poster display session

Presenters

Aheisha Wardak

Citation

Annals of Oncology (2017) 28 (suppl_5): v595-v604. 10.1093/annonc/mdx391

Authors

A. Wardak1, N. Willumsen2, D.J. Mogensen1, S.H. Nielsen1, C. Jensen1, S. Kehlet1, M.A. Karsdal1

Author affiliations

  • 1 Biomarkers & Research, Nordic Bioscience A/S, 2730 - Herlev/DK
  • 2 Cancer, Nordic Bioscience A/S, 2730 - Herlev/DK
More

Resources

Abstract 4425

Background

Type VI collagen (COL6) is emerging as an important component of the tumor microenvironment. The rationale that COL6 derived protein fragments may possess pro-tumorigenic properties has ample precedent (e.g. endothrophin). Little is however known, regarding COL6 degradation fragments as biomarkers for cancer. Here we address the biomarker potential of three specific COL6 degradation fragments measured in serum: Pro-C6 (C-terminal of the α3 chain/endotrophin), C6Ma3 (MMP-generated neo-epitope on the α3 chain), C6M (MMP-generated neo-epitope on the α1 chain).

Methods

Pro-C6, C6Ma3 and C6M were measured by validated competitive ELISAs in serum from patients with various stage solid tumors prior to treatment and healthy controls (table).

Results

C6M and C6Ma3 were significantly elevated (Kruskal-Wallis test) in most cancer types compared to controls, whereas Pro-C6 was not (table). A trend (p = 0.098) toward higher Pro-C6 was seen in the late (3/4) vs early (1/2) stage (Mann-Whitney test), whereas no difference was seen with C6M (p = 0.822) and C6Ma3 (p = 0.458). AUROC was 0.89 (p 

Conclusions

Specific type VI collagen fragments were increased in serum from cancer patients compared to healthy controls, and showed promising clinical accuracy. This clearly support COL-6 remodeling/degradation as an important component in understanding tumorgenesis. Future studies will determine biological and clinical applicability of quantifying various COL-6 fragments in serum in relation to cancer.

Clinical trial identification

Legal entity responsible for the study

Nordic Bioscience

Funding

None

Disclosure

A. Wardak, N. Willumsen, D.J. Mogensen, S.H. Nielsen, C. Jensen, S. Kehlet, M.A. Karsdal: Employed by Nordic Bioscience involved in biomarker development

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.